US FDA Tech Modernization Plan’s Costs Uncertain
Agency officials determining needs using existing budgets before requesting more funds and will engage with tech investors for design advice.
You may also be interested in...
US FDA wants to use biosimilars for a demonstration of cloud-based technology, an idea mentioned to increase the use of real-time review and enhance data analysis.
As agency prepares to hear from stakeholders on its strategy, real-world data precedents already are being set thanks to COVID-19, Aetion tells the Pink Sheet.
As the agency and country plot the steps to reopening, a full resumption of activities still seems a long way off.